Millennium Management’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $24.4M | Sell |
54,600
-8,200
| -13% | -$3.82M | 0.01% | 1385 |
|
|
2025
Q4 | $28.5M | Sell |
62,800
-67,800
| -52% | -$29.2M | 0.01% | 1229 |
|
|
2025
Q3 | $51.1M | Buy |
130,600
+24,900
| +24% | +$10.4M | 0.02% | 856 |
|
|
2025
Q2 | $47.1M | Sell |
105,700
-22,700
| -18% | -$10.5M | 0.02% | 860 |
|
|
2025
Q1 | $62.3M | Buy |
128,400
+90,300
| +237% | +$42.1M | 0.03% | 613 |
|
|
2024
Q4 | $15.3M | Buy |
38,100
+25,400
| +200% | +$11.8M | 0.01% | 1745 |
|
|
2024
Q3 | $5.91M | Sell |
12,700
-144,400
| -92% | -$69.4M | ﹤0.01% | 2698 |
|
|
2024
Q2 | $73.6M | Buy |
157,100
+22,800
| +17% | +$9.9M | 0.03% | 571 |
|
|
2024
Q1 | $56.1M | Sell |
134,300
-17,800
| -12% | -$7.52M | 0.02% | 757 |
|
|
2023
Q4 | $61.9M | Sell |
152,100
-26,800
| -15% | -$9.9M | 0.03% | 668 |
|
|
2023
Q3 | $62.2M | Buy |
178,900
+48,400
| +37% | +$16.9M | 0.03% | 571 |
|
|
2023
Q2 | $45.9M | Sell |
130,500
-10,900
| -8% | -$3.67M | 0.02% | 792 |
|
|
2023
Q1 | $44.6M | Buy |
141,400
+70,800
| +100% | +$21.2M | 0.03% | 769 |
|
|
2022
Q4 | $20.4M | Buy |
70,600
+62,100
| +731% | +$18.9M | 0.01% | 1435 |
|
|
2022
Q3 | $2.46M | Sell |
8,500
-34,900
| -80% | -$10M | ﹤0.01% | 3560 |
|
|
2022
Q2 | $12.2M | Buy |
+43,400
| New | +$11.6M | 0.01% | 1797 |
|
|
2021
Q4 | – | Sell |
-45,200
| Closed | -$8.2M | – | 7429 |
|
|
2021
Q3 | $8.2M | Sell |
45,200
-110,000
| -71% | -$21.5M | ﹤0.01% | 2319 |
|
|
2021
Q2 | $31.3M | Sell |
155,200
-13,800
| -8% | -$2.89M | 0.02% | 870 |
|
|
2021
Q1 | $36.3M | Buy |
169,000
+59,000
| +54% | +$13M | 0.03% | 672 |
|
|
2020
Q4 | $26M | Sell |
110,000
-1,200
| -1% | -$275K | 0.02% | 879 |
|
|
2020
Q3 | $30.3K | Buy |
111,200
+26,200
| +31% | +$7.23M | 0.04% | 554 |
|
|
2020
Q2 | $24.7M | Buy |
85,000
+35,000
| +70% | +$9.49M | 0.03% | 622 |
|
|
2020
Q1 | $11.9M | Sell |
50,000
-50,000
| -50% | -$11.5M | 0.03% | 741 |
|
|
2019
Q4 | $21.9M | Buy |
+100,000
| New | +$20.2M | 0.03% | 789 |
|
|
2019
Q3 | – | Sell |
-100,000
| Closed | -$18.3M | – | 4588 |
|
|
2019
Q2 | $18.3M | Sell |
100,000
-65,000
| -39% | -$11.4M | 0.03% | 844 |
|
|
2019
Q1 | $30.4M | Buy |
165,000
+65,000
| +65% | +$12M | 0.05% | 558 |
|
|
2018
Q4 | $16.6M | Sell |
100,000
-1,000
| -1% | -$173K | 0.03% | 801 |
|
|
2018
Q3 | $19.5M | Sell |
101,000
-49,000
| -33% | -$8.73M | 0.02% | 857 |
|
|
2018
Q2 | $25.5M | Buy |
150,000
+73,100
| +95% | +$11.3M | 0.03% | 732 |
|
|
2018
Q1 | $12.5M | Buy |
76,900
+71,900
| +1,438% | +$11.7M | 0.02% | 1180 |
|
|
2017
Q4 | $749K | Sell |
5,000
-30,000
| -86% | -$4.44M | ﹤0.01% | 2880 |
|
|
2017
Q3 | $5.32M | Sell |
35,000
-95,000
| -73% | -$14.3M | 0.01% | 1634 |
|
|
2017
Q2 | $16.8M | Buy |
130,000
+25,000
| +24% | +$3.01M | 0.03% | 760 |
|
|
2017
Q1 | $11.5M | Buy |
105,000
+55,000
| +110% | +$4.84M | 0.02% | 943 |
|
|
2016
Q4 | $3.68M | Buy |
50,000
+10,000
| +25% | +$814K | 0.01% | 1535 |
|
|
2016
Q3 | $3.49M | Sell |
40,000
-10,000
| -20% | -$945K | 0.01% | 1585 |
|
|
2016
Q2 | $4.3M | Buy |
+50,000
| New | +$4.32M | 0.01% | 1344 |
|
|
2014
Q4 | – | Sell |
-50,000
| Closed | -$5.62M | – | 4297 |
|
|
2014
Q3 | $5.62M | Sell |
50,000
-343,900
| -87% | -$32.7M | 0.01% | 1220 |
|
|
2014
Q2 | $37.3M | Buy |
393,900
+316,700
| +410% | +$22.2M | 0.1% | 224 |
|
|
2014
Q1 | $5.46M | Buy |
+77,200
| New | +$6.11M | 0.02% | 1166 |
|
|
2013
Q3 | – | Sell |
-40,300
| Closed | -$3.23M | – | 3604 |
|
|
2013
Q2 | $3.23M | Buy |
+40,300
| New | +$2.97M | 0.01% | 1291 |
|
Other funds holding VRTX
VCM
VPM
Millennium Management's VRTX Position: Q1 2026 in Review
Millennium Management reduced its Vertex Pharmaceuticals (VRTX) stake by 92% in Q1 2026, selling an estimated $156M and leaving 30,823 shares worth $13.8M. The position accounts for 0.01% of the portfolio, ranked #1864.
Millennium Management first reported a position in VRTX in Q2 2013 and has held it in 51 quarters since. The position peaked at $375M in Q2 2023. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.
- Millennium Management held 30,823 shares of Vertex Pharmaceuticals worth $13.8M as of Q1 2026.
- Millennium Management sold 334,841 Vertex Pharmaceuticals shares in Q1 2026, an estimated $156M.
- Vertex Pharmaceuticals made up 0.01% of Millennium Management's portfolio in Q1 2026, its #1864 holding.
- Millennium Management first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 51 quarters since.
- Millennium Management's Vertex Pharmaceuticals position peaked at $375M in Q2 2023.
- 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.
Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.